Novasign accelerates bioprocess development with AI-powered, hybrid-model digital twins.

Our software and services combine first-principles models with machine learning to design, simulate, and optimize upstream and downstream operations for early and late-stage development as well as for manufacturing — cutting experiments, timelines, and costs. The Novasign Studio platform (cloud/on-prem) supports model-based DoE, end-to-end process simulation, monitoring, and predictive control across cultivation, harvest, filtration, and chromatography.

We are already supporting several TOP25 pharma companies by reducing their experimental effort by up to 70%, easing scale-up, and developing strategies for fully autonomous manufacturing. In addition to biopharma, we also collaborate with industrial biotech and cultured food companies to accelerate innovation and improve process efficiency.